

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number  
**WO 2004/019913 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/127**
- (74) Agents: ARNAUD, Antonio, M., P. et al.; Rua José Bonifácio, 93 - 9th floor, 01003-901 São Paulo - SP (BR).
- (21) International Application Number:  
PCT/BR2003/000123
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 28 August 2003 (28.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
P 02 01 03264 29 August 2002 (29.08.2002) AR
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*): MONTE VERDE S.A. [AR/AR]; Cabildo 86, C1426AAN Ciudad Autónoma de Buenos Aires (AR). ZODIAC PRODUTOS FARMACÊUTICOS S.A. [BR/BR]; Rua Venancio Ayres, 417 - Perdizes, 05024-030 São Paulo - SP (BR).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): MAMMARELLA, Carlos, Alberto, Genaro [AR/AR]; Gregorio de Laferrere 1593, 2do Piso, 1406 Ciudad Autónoma de Buenos Aires (AR).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2004/019913 A1

(54) Title: A PHARMACEUTICAL COMPOSITION OF SMALL-SIZED LIPOSOMES AND METHOD OF PREPARATION

(57) Abstract: A pharmaceutical composition of small sized unilamellar liposomes for the supply active principles by injection, with an improved permanency in the blood flow, where the unilamellar membrane contains a mixture of saturated lipids encompassing at least one lysophospholipid in a quantity from about 0.5 mol% to about 6,0 mol % with reference total lipids and the production method. Additionally, liposomes of high encapsulation efficiency of an active principle like doxorubicine are prepared through the adding of a solution of calcium ions.

Best Available Copy

A PHARMACEUTICAL COMPOSITION OF SMALL-SIZED LIPOSOMES  
AND METHOD OF PREPARATION

Field of the invention

The present invention refers to novel compositions of  
5 small-sized liposomes, with the aim to supply active  
compounds by injectable route, especially for  
therapeutical applications, with enhanced permanency  
in blood. In addition, a preparation method for  
liposomes with high incorporation efficiency of the  
10 active principle within the liposomes, is provided.

Background of the invention

Most of the drugs administered by perfusion or through  
injection, have at least, one of the following  
drawbacks:

- 15 1) they are rapidly eliminated from the circulation,  
or
- 2) they have a low therapeutic index (particularly due  
to a high toxicity, to a high incidence of adverse  
effects compared to its therapeutic efficiency or to a  
20 bad distribution).

In this context, liposomes have been widely used as  
systems for the controlled and sustained delivery of  
active principles.

Liposomes are essentially lipidic vesicles, suspended  
25 in an aqueous medium, containing an entrapped aqueous  
volume within them.

Liposomes are essentially completely closed spherical  
structures formed by double-layer lipid membranes.  
Liposomes may be unilamellar vesicles (possessing a  
30 single membrane bilayer) or multilamellar vesicles  
(onion-like structures characterized by multiple  
membrane bilayers, each separated from the next by an  
aqueous layer). The bilayer is composed of two  
monolayers of molecules of a particular type, having a  
35 hydrophobic ("tail") region and a hydrophilic (head)

region. This type of molecules is called amphipatic. The structure of the membrane bilayer is such that the hydrophobic (non polar) "tails" of the lipid monolayers orient toward the center of the bilayer while the hydrophilic (polar) "heads" orient towards the aqueous phase. The resulting structure is an energetically stable, closed structure able to transport bioactive molecules. Thus, the bioactive molecules trapped in the liposomes may present a better therapeutic index, as well as an improved bio-distribution. The drugs transported by liposomes are gradually delivered to the circulation, lessening the toxic side effects associated with the administration of the free drug.

The liposomes are extensively used for the preparation of pharmaceutical formulations, to supply a variety of active agents of diagnostic and therapeutical value in a selective manner.

Liposomes constituted by different lipids were described in the prior art, for example in US Patents No. 4,737,323 (1988), 4,769,250 (1988), 4,837,028 (1989), 4,863,739 (1989), 4,920,016 (1990), 5,013,556 (1991), 5,463,066 (1995). At the same time, different methods and variants thereof, are known for the preparation of different types of liposomes, such as the ones described in the following publications: Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, by Olson, F., Hunt, C.A., Szoka, F.C, Vail, W.J., Papahadjopoulos, D., Biochem. Biophys. Acta, 557, 9 - 23 (1979), Vesicles of variable size produced by a rapid extrusion procedure, by Mayer, L.D., Hope, M.J. Cullis, P.R. Biochem. Biophys. Acta 858, 161-168 (1986), and Effects of soluble concentrations on the entrapment of solutes in phospholipids vesicles

prepared by freeze-thaw extrusion, by Chapman, C.J.; Erdahl, E.E.; Taylor, R.W; Pfeiffer, D.R.; Chem. Phys. Lipids, 60, 201-208 (1991). Additional bibliographical information may be found in: N. Berger, A. Sachse, J. Bender, R. Schbert and M. Branddl, Int. J. Pharmaceutics, 223, 55-68 (2001).

Some patents, such as for example US Patent 5,043,164, describe liposome compositions containing lysophospholipids. Said patent describes a composition for liposomes containing a phosphatidyl ethanolamine (particularly dioleoyl phosphatidyl ethanolamine) and a fatty acid, such as oleic acid. According to the disclosure of the above mentioned patent, with the aim of stabilizing the liposomes, cholesterol (a conventional stabilizing agent) is replaced by an amphypatic substance, such as, lysophospholipids, gangliosides, sulphatides, lyophilic drugs and amphipathic proteins wherein the ratio of lipids: amphypatic substance is from about 10:1 to 1:1 w/w and wherein said amphypatic substance is added a short time after the preparation of the liposomes.

On the other hand, US Patent 5,009,956 describes a method to stabilize liposome membranes using a mixture of a phospholipid and between 20-30 mol% of a lysophospholipid, wherein at least one of them is unsaturated.

As mentioned above, liposomes have been extensively used as systems for the controlled and sustained release of active compounds retained inside the liposomes during a prolonged period of time. In this way, by limitation of the concentration of free drug in the blood flow, the possible toxic effects of drug, are reduced. Nevertheless, a frequent problem of this strategy emerges through the swift elimination of liposomes by the reticular endothelial system (RES) and

the low retention of the active principles.

One of the factors contributing to reduce to a minimum the removal of the liposomes by the RES is the liposome preparation of small and uniform size.

- 5 Another factor contributing to improve the therapy of the delivery of active compounds, constitutes the possibility of obtaining liposomes with an improved efficiency to load active compounds, thus enhancing the amount of active compound entrapped inside the  
10 liposome vesicles.

Summary of the invention

The present invention provides a pharmaceutical composition of small-sized unilamellar liposomes for the delivery of an injectable active compound.

- 15 According to the present invention, liposomes of small size are obtained by the addition of limited quantities of a lysophospholipid to the lipid mixture that constitutes the membrane formulation.

- Thus, it is an object of the present invention, to  
20 provide a pharmaceutical composition of small-sized, sucrose liposomes for a parenteral administration of an active compound, which comprises: (i) liposomes with an average diameter of about 75 nm to about 300 nm, wherein the unilamellar membrane is formed by a  
25 mixture of saturated lipids containing a ratio of lysophospholipids of about 0,5 mol% to about 6,0 mol% of the total lipids content, and (ii) an encapsulated therapeutic compound contained in said liposomes.

- Preferred concentrations of lysophospholipids are  
30 those of about 1,4 mol% and about 2,8 mol% regarding the total lipid content.

- It is another object of the invention to provide a method for the preparation of small sized liposomes, wherein said method is controlled through a simple  
35 procedure, by the adding of small quantities of a

lysophospholipid to the lipidic mixture used in said preparation.

In a particular embodiment of the invention, it is provided a pharmaceutical composition of unilamellar liposomes of small size, for a parenteral administration of a cytotoxic agent, wherein said cytotoxic agent is preferably an anthracyclenic antibiotic such as doxorubicin, epirubicin or daunorubicin. In a preferred embodiment of the invention, doxorubicin is used.

Another outstanding aspect of the present invention is a method for the preparation of a liposome composition aimed to enhance the amount of encapsulated doxorubicine in the liposomic vesicles. Such improvement in the efficiency of doxorubicin incorporation into the liposomes is obtained by adding calcium ions to the doxorubicin solution during the step of loading the liposomes with active principle.

#### Detailed description of the drawings

Figure 1 shows the size distribution curves of liposomes for increasing quantities of lysophospholipids, as a function of the pore size of the extruding polycarbonate membrane.

Figures 2a y 2b show the size distribution of extruded liposomes through membranes with decreasing pore size (in this case the smaller size pore depicted is 200 nm), with addition of lysophospholipid (batches 06012 and 06013) and without the addition of lysophospholipid (batch 06011).

#### Detailed description of the invention

The liposomes of the present invention are unilamellar liposomes having a single double layer membrane. The bilayer is composed of two monolayers of molecules of a particular type (amphipathic molecules), having a hydrophobic ("tail") region and a hydrophilic (head)

region. The structure of the bilayer membrane is such that the hydrophobic (non polar) "tails" of the lipid monolayers orient toward the center of the bilayer while the hydrophilic (polar) "heads" orient towards the aqueous phase. The resulting structure is an energetically stable, closed structure, able to transport bioactive molecules.

The unilamellar membrane of this invention is formed by a mixture of saturated lipids. According to the present invention, small-sized liposomes are obtained by adding lysophospholipids to the mixture of lipids used for the preparation of liposomal membrane.

Preferably, the lysophospholipids are selected from lysophosphatidylcholine, lysophosphatidylinositol, lysophosphatidylserine and lysophosphatidic acid.

Lysophosphatidylcholine (Lyso PC), is obtainable by chemical synthesis or by enzymatic hydrolysis with phospholipase A2. Naturally it is also produced as a degradation product of phosphatidylcholine.

The lipids used for the preparation of the unilamellar membrane are saturated lipids, preferably selected among phosphatidylcholine, cholesterol and phosphatidyl ethanolamine, phosphatidylinositol, phosphatidylglycerol, natural phosphatidylcholine (from soybean and/or eggs) and hydrogenated phosphatidylcholine obtained from different natural sources like soybean or eggs, distearoyl fosfatidylethanolamine derivatized with polyethyleneglycol 2000 - O-methylated and/or glycolipids like GM1 or other sialogangliosides, or combinations thereof.

It was found experimental evidence that the addition of increasing, but limited quantities of a lysophospholipid to the mixtures of lipids used in the preparation of liposomes, produce a reduction of the

liposomes size, when they are compared to those produced using the same mixture of lipids without the addition of lysophospholipids.

As used herein, liposomes of small size are liposomes  
5 presenting an average diameter lower than about 500 nm, preferably an average diameter that ranges from about 75 nm to about 300 nm. Big size liposomes are those having an average diameter of about 500 nm. The average diameter may be determined through  
10 conventional, well-known methods, for the skilled in the art. Among such methods, electronic microscopy and dynamic laser light dispersion may be mentioned. (Laser Light Scattering).

According to the present invention, liposomes of small  
15 size are obtained by the addition of lysophospholipids to the lipid mixture that will conform the liposomal membrane, preferably with a content of lysophospholipid which varies between about 0,5 mol% and about 6,0 mol% related to the total amount of  
20 lipid content. Most preferably, the content of lysophospholipids could be from about 1,4 mol% to about 2,8 mol%, related to the total amount of lipid content.

Sterols may be conveniently added to the mixture of  
25 lipids. Particularly, cholesterol could be added. The addition of cholesterol increases the stability of the liposomal vesicles, improving the retention of the active principle.

Liposomes are prepared through generally known  
30 techniques. Particularly, for the preparation of liposomes of the present invention, a procedure combining freezing/unfreezing cycles with extrusion through membranes of different pore size is preferred. Most preferably, a combination of a homogenization  
35 procedure, carried out with an appropriate



homogeneizer, and extrusion through membranes of different pore size could be used.

Preferably, the lipid mixture is dissolved in an organic solvent which is evaporated up to dryness.

5 The lipidic membrane formed is taken up with an aqueous solution, the suspension being subjected to 3 and 6 freezing cycles (from about -20°C to -45°C) and unfreezing (up to 50°C - 60°C). Afterwards, the suspension is extruded through polycarbonate  
10 membranes [Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes, by Olson F., Hunt, C.A., Szoka, F.C., Vail, W.J., Papahadjopoulos, D., Biochem. Biophys. Acta, 557, 9-23 (1979); Vesicles of variable size produced  
15 by a rapid extrusion procedure, by Mayer, L.D., Hope, M.J., Cullis, P.R.; Biochem. Biophys. Acta 858, 161-168 (1986)]. In the present invention, extrusion starts with the membrane of biggest pore, e.g. 1000 nm, followed by a membrane of smaller pore (400 nm)  
20 and following with membranes of the smallest pore size, until liposomes of the desired size are obtained.

The incorporation of the active agent inside the liposomes is made, according to the present invention;  
25 by the method of active loading, after the dialysis of the liposome suspension, by known procedures for the skilled in the art.

The efficiency of loading of an active agent into a liposome also depends on the chemical properties of  
30 the compound. Generally, compounds soluble in water or soluble in lipids are of easier incorporation. Compounds soluble in lipids could be easily incorporated into the lipidic bilayer during the formation of the liposome (passive loading). On the  
35 other hand, compounds soluble in water interact with

the polar head of the phospholipid which is confronted with in the interior of the liposome and therefore the compound is easily sequestered in the inside of the liposome. The amphypatic compounds, such as the anthracyclenic antibiotics are the most difficult to retain inside the liposomes.

In another embodiment of the invention, it was found essential, for the supply of therapeutically effective doses of a variety of cytotoxic agents, to load the liposomes with high concentration of the active principle. For example, for cytotoxic agents such as anthracyclenic antibiotics, particularly anthracyclenic antibiotics such as doxorubicin, epirubicin, daunorubicin, salts thereof and similar compounds, it is desirable to obtain a ratio of encapsulated active principle of about 8,5% w/w to about 11.5% w/w referred to the weight of the lipid content of the liposomes.

A method for the active loading of amphypatic drugs in the liposome is described in U.S. Patent No. 5,192,542 (Barenolz et al.), which is incorporated herein as a reference. According to such method, liposomes are prepared in the presence of ammonium ions, for example in an ammonium sulfate solution or in the presence of any other ammonium compound solution which is able to dissociate within the liposomes, such as phosphate, carbonate and bicarbonate solutions. After achieving the adequate size, the liposome suspension is treated so as to create a gradient of ammonium ions through the liposomal membrane.

Surprisingly, and according to a particular embodiment of the present invention, it was discovered that when the doxorubicin loading within the liposomes is performed in presence of small concentrations of calcium ions, the efficiency of encapsulation is

remarkably enhanced.

Particularly preferred starting calcium ions solutions are calcium chloride solutions at a concentration from about 50 mM to about 200 mM. Other soluble salts of calcium may be used. pH Buffering components, when they are used, shall not include sequestering calcium substances. Acetic/acetate solutions as well as any other anion solution which do not produce calcium ion precipitation may be used. An amino acid, such as histidine, could also be used. The ratio of liposome solution to calcium chloride solution may be of about 1,5 to 0.05 - 0,5 (v/v).

Without adhering to a particular theory, it is understood that the presence of calcium ions would allow the elimination of the remaining of ammonium sulfate from the outside of the lipidic vesicles, since in the presence of same, doxorubicin gellifies, and in such a case it would not be available to permeate to the interior of the liposomes. The elimination of the remaining ammonium ions to the immediate exterior zone of liposomes, would free doxorubicin to incorporate inside the liposomes.

Therefore, a method to improve the yield of incorporation of the active principle inside the liposomes is achieved, increasing the percentage of encapsulated active principle from of about 20 to about 70%, when compared to the incorporation obtained by a method which does not use calcium ions.

The following specific examples are provided as exemplary of the invention but are not limitative.

#### EXAMPLES.

##### Control preparation

A solution containing 95 mg of hydrogenated soybean phosphatidyl choline, 30 mg of phosphatidyl ethanolamine derivatized with O-methyl-

polyethylenglycol-2000 and 30 mg of cholesterol in 15 ml of ethanol anhydrous is prepared.

The mixture is evaporated in a rotatory evaporator up to dryness, trying not to exceed a temperature of 45°C. The formed film is taken up in an ammonium sulfate solution at 45°C (5 ml of a solution containing about 13,2 mg/l), with stirring at room temperature.

The liposomes obtained in the previous step, are subjected to freezing (-45°C) and unfreezing (thawing) (50°C) cycles. At least 6 cycles are performed.

Afterwards they are extruded through decreasing pore membranes, starting through a membrane of 1000 nm, afterwards 400 nm and finally through a membrane of 200 nm.

The average size of the liposomes in this preparation was determined by the method of Laser Light Scattering. The result is shown in figure 1 with a full circle (0 mol% of lysophospholipid /total lipids).

#### Example 1

A solution containing 95 mg of hydrogenated soybean phosphatidylcholine, 1,5 mg of palmitoyl lysophosphatidyl choline, 30 mg of phosphatidyl ethanolamine derivatized with O-methyl polyethileneglycol-2000 and 30 mg of cholesterol in 15 ml of anhydrous ethanol is prepared.

The mixture is evaporated in a rotatory evaporator up to dryness, at a temperature not higher than 45°C. The film formed is taken up in a solution of ammonium sulfate at 45°C (5 ml of a solution containing 13,20 mg/l) under stirring at room temperature. The liposomes obtained in the previous step are submitted to freezing (-45°C) and thawing (50°C) cycles. At least 6 cycles are performed.

Afterwards extrusion through decreasing pores membranes is performed, starting with membranes of 1,000 nm, following with a membrane of smaller pore size (400 nm) and finally through a 200 nm membrane.

- 5 The average size of liposomes in this preparation is shown in Figure 1 with an empty circle (1,43 mol% of lysophospholipid/ total lipids.)

Example 2

A solution containing 95 mg of hydrogenated soybean  
10 phosphatidylcholine, 3 mg of palmitoyl  
lysophosphatidyl choline, 30 mg of phosphatidyl  
ethanolamine derivatized with O-methyl  
polyethyleneglycol-2000 and 30 mg of cholesterol in 15  
ml of anhydrous ethanol is prepared.

- 15 The mixture is evaporated in a rotatory evaporator until dryness, at a temperature not higher than 45°C. The formed film is taken up in a solution of ammonium sulfate at 45°C (5 ml of solution containing 13,20 mg/l), under stirring at room temperature.

- 20 The liposomes obtained in the previous step are submitted to freezing (-45°C) and thawing cycles (50°C). At least 6 cycles are performed.

Afterwards extrusion through decreasing pores membranes is performed, starting with membranes of  
25 1000 nm, following with a membrane of smaller pore size (400 nm) and finally through a 200 nm membrane.

The average size of the liposomes obtained in this preparation is shown in Figure 1, with a full triangle (2.86 mol% of lysophospholipid/ total lipids)

30 Example 3

A solution containing 95 mg of hydrogenated soybean  
phosphatidylcholine, 14 mg of palmitoyl  
lysophosphatidyl choline, 30 mg of phosphatidyl  
ethanolamine derivatized with methyl  
35 polyethyleneglycol-2000 and 30 mg of cholesterol in 15

ml of anhydrous ethanol is prepared.

The mixture is evaporated in a rotatory evaporator up to dryness, trying to perform it at a temperature not higher than 45°C. The formed film is taken up in  
5 solution of ammonium sulfate at 45°C (5 ml of solution containing 13,20 mg/l), with stirring at room temperature.

The liposomes obtained in the previous step are submitted to freezing (-45°C) and thawing  
10 (50°C) cycles. At least 6 cycles are performed.

Afterwards, extrusion through decreasing pores membranes is performed, starting with membranes of 1,000 nm, following with a membrane of smaller pore size (400 nm) and finally through a 200 nm membrane.

15 The average size of liposomes in this preparation is shown in Figure 1 with a void triangle (11,5 mol% of lysophospholipid /total lipids).

#### Example 4

A solution containing 95 mg of hydrogenated soybean  
20 phosphatidylcholine, 18mg of palmitoyl lysophosphatidyl choline, 30 mg of phosphatidyl ethanolamine derivatized with O-methyl polyethylenglycol 2000 and 30 mg of cholesterol in 15 ml of anhydrous ethanol is prepared.

25 The mixture is evaporated in a rotating evaporator up to dryness, at a temperature not higher than 45°C. The film formed is taken up in solution of ammonium sulfate at 45°C (5 ml of a solution containing 13,20 mg/l), with stirring at room temperature.

30 The liposomes obtained with the former step are submitted to freezing (-45°C) and thawing (50°C) cycles. At least 6 cycles are performed.

Afterwards extrusion through decreasing pores membranes is performed, starting with membranes of  
35 1,000 nm, following with a membrane of smaller pore

size (400 nm) and finally through a 200 nm membrane. The average size of the liposomes in this preparation is shown in Figure 1 with a full square (14,3 mol% of lysophospholipid / total lipids).

- 5 On Table 1 the measured sizes of liposomes containing progressive quantities of lysophospholipids after extrusion through membrane of 400 nm, according to the description of the previous examples and Figure 1, are shown.

10 Table 1

Example No.	Lyso content in mol% (Lyso PC/Total lipids)	PC in	Size measured of liposomes containing progressive quantities of Lyso PC after extrusion through membrane of 400 nm
Control	---		310 nm
1	1,43		215 nm
2	2,86		240 nm
3	11,5		208 nm
4	14,3		75 nm

Example 5

- Two batches of liposomes (06012 and 06013) are prepared according to the procedure described in Example 1. Also a liposome batch is prepared, in accordance to the process described in the item "Control preparation" (Batch 06011). Figures 2a and 2b depict the distribution of particle size for batches 06012 and 06013, compared with the distribution of particle size for batch 06011 (Control without lysophospholipid).
- 15
- 20

A consistency of results is observable between the liposome batches containing lysophospholipid. In both batches (06012 and 06013), a smaller size of particles than the corresponding to the control preparation without lysophospholipid (06011), can be seen.

25

Example 6

A liposome suspension obtained as described in Example 1 is dialyzed against a solution of sucrose 10% (w/v) in order to eliminate the ammonium sulfate on the outside of the liposomes.

Afterwards, a solution containing the following composition is prepared: 1,5 volumes of liposomes in suspension, 1 volume of a doxorubicin hydrochloride solution containing 6 mg/ml of said compound in a sucrose solution 10% (w/v) and histidine 0,15% (w/v) and 0,5 ml of a solution of sucrose 10% /histidine 0,15% (w/v) (buffer sucrose/histidine).

The mixture is settled during 15 minutes, and warmed up lightly.

The degree of encapsulated doxorubicin hydrochloride is determined by UV spectrometry (absorbancy at 590 nm). With this purpose, absorbancy determinations on samples of liposomes with encapsulated doxorubicin dilutions in alkaline isotonic medium (free of doxorubicin) and on samples of liposome with encapsulated doxorubicine dilutions in alkaline medium containing detergent (total doxorubicin) are performed. Through the absorbancy data obtained at 590 nm the percentage of encapsulation of 78,7% is calculated. The percentage of free doxorubicin is 21,3%.

Example 7

A suspension of dialyzed liposomes is prepared as described in Example 5, and afterwards said suspension is incubated, according to the following ratios:

1,5 volumes of liposomes suspension, 0,4 volumes of sucrose/histidine buffer (according to example 5), 0,1 volumes of solution 100 mM of  $Cl_2Ca$  and 1,0 volume of doxorubicin hydrochloride solution, 6 mg/ml in sucrose /histidine buffer.



The mixture is left setting during 15 minutes, with light warming.

The percentage of doxorubicin incorporated is determined (as depicted in example 5), obtaining a value of 87,9%. The percentage of free doxorubicin is 12,1%. As can be seen, the degree of incorporation is 9,2 points higher than the one obtained without Cl<sub>2</sub>Ca.

Example 8

A process according to Example 5 is used. Once incubation is finished, dialysation against a buffer solution of sucrose/histidine during 12 hours is performed.

The percentage of encapsulation of doxorubicin hydrochloride is 91,2%.

Example 9

A process according to Example 6 is used, and finally it is dialyzed against a buffer solution of sucrose/histidine during 12 hours.

The percentage of encapsulated doxorubicine is 95,53%, e.g. 4,33 points higher than without the adding of calcium chloride. In other words, the percentage of free doxorubicin is 50% less than without the addition of calcium chloride.

While the invention has been described in detail, with specific reference to process realizations and particular procedures, it will be noted that different alterations, modifications and adaptations may be based on the present description and are included in the spirit and scope of the present invention as defined in the following claims.

CLAIMS

1. A pharmaceutical composition of small-sized, unilamellar liposomes, for parenteral administration of an active compound, comprising: liposomes with an  
5 average diameter from about 75 nm to about 300 nm, wherein the unilamellar membrane contains a mixture of saturated lipids, said unilamellar membrane containing at least one lysophospholipid in an amount of about 0,5 mol% to 6.0 mol% regarding the total lipid  
10 content, and a therapeutic encapsulated compound included inside said liposomes.
2. A composition according to claim 1, wherein the lysophospholipid is selected from lysophosphatidylcholine, lysophosphatidylinositol,  
15 lysophosphatidylserine and lysophosphatidic acid or combinations thereof.
3. A composition according to claim 1, wherein the saturated lipids are selected from phosphatidylcholine, cholesterol,  
20 phosphatidylethanolamine, phosphatidylinositol, phosphatidylglycerol, natural phosphatidylcholine (soy and/or egg), distearoyl phosphatidylethanolamine derivatized with O - methylated polyethyleneglycol 750-5000, dipalmitoyl phosphatidylethanolamine  
25 derivatized with O-methylated polyethyleneglycol 750-5000 or combinations thereof.
4. A composition according to claim 3, wherein distearoyl phosphatidylethanolamine is derivatized with O-Methyl-polyethylene-glycol 2000
- 30 5. A composition according to claim 3, wherein dipalmitoyl phosphatidyl ethanolamine is derivatized with O-methyl-polyethylene-glycol 2000
6. A composition according to claim 1, wherein the active principle is a cytotoxic agent.
- 35 7. A composition according to claim 6, wherein the

cytotoxic agent is selected from anthracyclenic antibiotics, taxanes and platinum salts.

8. A composition according to claim 7, wherein the anthracyclenic antibiotic is selected from the group consisting in doxorubicin, epirubicin and daunorubicin and pharmaceutically acceptable salts thereof.

9. A pharmaceutical composition of unilamellar, small sized liposomes for parenteral administration of an active compound, according to claim 1, comprising:  
10 liposomes with an average diameter from about 75 nm to about 300 nm, wherein said unilamellar membrane contains a mixture of saturated lipids, comprising at least one lysophospholipid in an amount of about 0,5 mol% to about 6,0 mol% related to the total lipid  
15 content, and encapsulated doxorubicin inside said liposomes in a ratio of about 8,5% by weight to about 11,5% by weight related to the total weight of lipids in the liposomes.

10. A method of preparing a composition according to  
20 claim 1, comprising the steps of: forming liposomes from a solution containing saturated lipids and at least a lysophospholipid in an amount of about 0,5 mol% and 6,0 mol% regarding the total lipid content, and evaporation to dryness; taking the film up in  
25 aqueous solution; submitting the foregoing solution to freezing and thawing cycles extruding through membranes of decreasing pore up to a membrane of 50 nm pore, obtaining liposomes with an average diameter of about 75 nm to about 300 nm, dialyzing the liposome  
30 suspension, and mixing the dialyzed liposome suspension with a solution of the active compound.

11. A method according to claim 10, wherein the lysophospholipid is selected among  
lysophosphatidylcholine, lysophosphatidylinositol,  
35 lysophosphatidylserine and lysophosphatidic acid.

12. A method of preparing a composition of claim 9, comprising the steps of: forming liposomes from a solution containing saturated lipids and at least a lysophospholipid in an amount of about 0,5 mol% to 6,0 mol% regarding the total lipid content, and evaporating to dryness; taking the film up in a solution of an ammonium salt; submitting the foregoing solution to freezing and thawing cycles extruding through membranes of decreasing pore up to a membrane of 50 nm pore, obtaining liposomes with an average diameter of about 75 nm to about 300 nm; dialyzing the liposome suspension against an aqueous solution without ammonium ions; mixing the dialyzed liposome suspension with a solution of about 50 mM to about 200 mM of a soluble calcium salt and a solution of doxorubicin at a concentration of about 2 to about 30 mg/ml, obtaining a percentage of more than 80% of encapsulation of doxorubicin.

13. A method according to claim 12, wherein the calcium salt is calcium chloride.

14. A method according to claim 12 or 13, wherein the volume ratio of calcium chloride solution to doxorubicin solution is of 1:10 (v:v).

15. A method according to claim 12, wherein the percentage of encapsulated doxorubicin increases between 20 to 70% in the presence of calcium chloride, compared to a method which does not use calcium chloride.

1/2




FIGURE 1

2/2




FIGURE 2a




FIGURE 2b

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 34597 A (DUKE UNIVERSITY) 13 August 1998 (1998-08-13) claims examples	1-15
Y	WO 95 13053 A (STATE UNIVERSITY OF NEW YORK) 18 May 1995 (1995-05-18) claims example 2 page 12, line 16 -page 13, line 27	1-15
Y	WO 88 06439 A (UNIVERSITY OF MINNESOTA) 7 September 1988 (1988-09-07) cited in the application claims	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

21 November 2003

Date of mailing of the international search report

03/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with location, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 07466 A (LIPOSOME TECHNOLOGY) 14 April 1994 (1994-04-14) claims page 41, line 6 - line 7 examples	1-15
A	WO 97 22333 A (NATIONAL RESEARCH COUNCIL,CA) 26 June 1997 (1997-06-26) claims page 1, line 15 - line 19	1-15
A	WO 95 31172 A (PHARES) 23 November 1995 (1995-11-23) claims	1-15
A	WO 94 26254 A (THE LIPOSOME COMPANY) 24 November 1994 (1994-11-24) claims	1-15
A	WO 91 05546 A (LIPOSOME TECHNOLOGY) 2 May 1991 (1991-05-02) claims	1-15
A	DATABASE WPI Section Ch, Week 199306 Derwent Publications Ltd., London, GB; Class B04, AN 1993-049210 XP002260547 & JP 05 000239 A (TAIYO KAGAKU KK), 8 January 1993 (1993-01-08) abstract	1-15
A	DATABASE WPI Section Ch, Week 198509 Derwent Publications Ltd., London, GB; Class B05, AN 1985-052231 XP002260550 & JP 60 007934 A (DAIICHI SEIYAKU CO), 16 January 1985 (1985-01-16) abstract	1-15



Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9834597		13-08-1998	US 5827533 A	27-10-1998
			AU 6319698 A	26-08-1998
			US 6296870 B1	02-10-2001
			WO 9834597 A1	13-08-1998
			US 5882679 A	16-03-1999
			US 6143321 A	07-11-2000
WO 9513053	A	18-05-1995	US 5415869 A	16-05-1995
			AU 1176995 A	29-05-1995
			CA 2153326 A1	18-05-1995
			DE 69425879 D1	19-10-2000
			DE 69425879 T2	08-02-2001
			EP 0683664 A1	29-11-1995
			JP 8508046 T	27-08-1996
			WO 9513053 A1	18-05-1995
WO 8806439	A	07-09-1988	WO 8806439 A2	07-09-1988
			US 5009956 A	23-04-1991
WO 9407466	A	14-04-1994	US 5356633 A	18-10-1994
			AT 152614 T	15-05-1997
			AU 5323194 A	26-04-1994
			CA 2146565 A1	14-04-1994
			DE 69310527 D1	12-06-1997
			DE 69310527 T2	04-12-1997
			EP 0662820 A1	19-07-1995
			ES 2104184 T3	01-10-1997
			WO 9407466 A1	14-04-1994
WO 9722333	A	26-06-1997	CA 2241247 A1	26-06-1997
			WO 9722333 A1	26-06-1997
			EP 0869773 A1	14-10-1998
			JP 2000502087 T	22-02-2000
			US 6132789 A	17-10-2000
			US 6403117 B1	11-06-2002
WO 9531172	A	23-11-1995	AT 172632 T	15-11-1998
			DE 69505656 D1	03-12-1998
			DE 69505656 T2	02-06-1999
			EP 0759736 A1	05-03-1997
			WO 9531172 A1	23-11-1995
WO 9426254	A	24-11-1994	AU 6833994 A	12-12-1994
			WO 9426254 A1	24-11-1994
			US 5683715 A	04-11-1997
WO 9105546	A	02-05-1991	US 5013556 A	07-05-1991
			AT 115401 T	15-12-1994
			AT 122229 T	15-05-1995
			AU 642679 B2	28-10-1993
			AU 6637490 A	16-05-1991
			AU 654120 B2	27-10-1994
			AU 6898291 A	16-05-1991
			CA 2067133 A1	21-04-1991
			CA 2067178 A1	21-04-1991
			DE 69015207 D1	26-01-1995
			DE 69015207 T2	04-05-1995
			DE 69019366 D1	14-06-1995

Patent document cited in search report		Publication date	Patent family member(s)	Publication date	
WO 9105546			DE 69019366 T2	05-10-1995	
			DK 496835 T3	17-07-1995	
			EP 0496813 A1	05-08-1992	
			EP 0496835 A1	05-08-1992	
			ES 2071976 T3	01-07-1995	
			FI 921763 A	21-04-1992	
			FI 921764 A	21-04-1992	
			GR 3017060 T3	30-11-1995	
			HK 14097 A	14-02-1997	
			IL 96069 A	08-12-1995	
			IL 96070 A	30-03-1995	
			JP 2889549 B2	10-05-1999	
			JP 10001431 A	06-01-1998	
			JP 5501264 T	11-03-1993	
			JP 2667051 B2	22-10-1997	
			JP 5505173 T	05-08-1993	
			JP 2001181214 A	03-07-2001	
			KR 134982 B1	22-04-1998	
			LU 88854 A9	11-03-1997	
			NO 921213 A	04-06-1992	
			NO 921214 A	01-06-1992	
			US 5527528 A	18-06-1996	
			WO 9105545 A1	02-05-1991	
			WO 9105546 A1	02-05-1991	
			US 5620689 A	15-04-1997	
			US 5225212 A	06-07-1993	
			US 5213804 A	25-05-1993	
			US 2001051183 A1	13-12-2001	
			US 5843473 A	01-12-1998	
			US 5356633 A	18-10-1994	
	<hr/>				
	JP 5000239	A	08-01-1993	JP 2010846 C	02-02-1996
			JP 7012424 B	15-02-1995	
<hr/>					
JP 60007934	A	16-01-1985	JP 1856735 C	07-07-1994	
			JP 4028412 B	14-05-1992	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**